HALOZYME THERAPEUTICS, INC. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for the quarter ending 2018-12-31 was 0.00 shares.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for the quarter ending 2018-09-30 was 0.00 shares.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for the quarter ending 2018-06-30 was 0.00 shares.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for the quarter ending 2018-03-31 was 11.50M shares.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for fiscal 2019 was 11.50M shares, a 0.00% change from fiscal 2018.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for fiscal 2018 was 11.50M shares, a 0.00% change from fiscal 2017.
- HALOZYME THERAPEUTICS, INC. stock issued during period, shares, new issues for fiscal 2017 was 11.50M shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2019-12-31 | 11.50M shares 10-K · filed 2020-02-24 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | 11.50M shares 10-K · filed 2019-02-21 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 11.50M shares derived: sum of 4 quarters · filed 2018-11-06 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 11.50M shares derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | 11.50M shares 10-Q · filed 2018-05-10 | |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | 11.50M shares 10-K · filed 2018-02-20 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |